BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25226731)

  • 1. Piperacillin-tazobactam as a cost effective monotherapy in febrile neutropenia.
    Fasih S; Siddiqui N; Muza N; Hannan A; Sarwar S; Shafi A; Athar S
    J Ayub Med Coll Abbottabad; 2013; 25(3-4):19-22. PubMed ID: 25226731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia.
    Zengin E; Sarper N; Kılıç SC
    Pediatr Hematol Oncol; 2011 May; 28(4):311-20. PubMed ID: 21524156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imipenem/cilastatin versus piperacillin/tazobactam plus amikacin for empirical therapy in febrile neutropenic patients: results of the COSTINE study.
    Sanz MA; Bermúdez A; Rovira M; Besalduch J; Pascual MJ; Nocea G; Sanz-Rodríguez C;
    Curr Med Res Opin; 2005 May; 21(5):645-55. PubMed ID: 15969864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan.
    Tamura K; Akiyama N; Kanda Y; Saito M
    J Infect Chemother; 2015 Sep; 21(9):654-62. PubMed ID: 26141812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
    Sezgin G; Acipayam C; Ozkan A; Bayram I; Tanyeli A
    Asian Pac J Cancer Prev; 2014; 15(11):4549-53. PubMed ID: 24969883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of piperacillin tazobactam and cefoperazone sulbactam monotherapy in treatment of febrile neutropenia.
    Karaman S; Vural S; Yildirmak Y; Emecen M; Erdem E; Kebudi R
    Pediatr Blood Cancer; 2012 Apr; 58(4):579-83. PubMed ID: 21674768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies.
    Bow EJ; Rotstein C; Noskin GA; Laverdiere M; Schwarer AP; Segal BH; Seymour JF; Szer J; Sanche S
    Clin Infect Dis; 2006 Aug; 43(4):447-59. PubMed ID: 16838234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
    Gorschlüter M; Hahn C; Fixson A; Mey U; Ziske C; Molitor E; Horré R; Sauerbruch T; Marklein G; Schmidt-Wolf IG; Glasmacher A
    Support Care Cancer; 2003 Jun; 11(6):362-70. PubMed ID: 12690546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
    Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
    Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study.
    Sano H; Kobayashi R; Suzuki D; Kishimoto K; Yasuda K; Kobayashi K
    Pediatr Blood Cancer; 2015 Feb; 62(2):356-358. PubMed ID: 25251104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
    Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
    Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
    Aamir M; Abrol P; Sharma D; Punia H
    Trop Doct; 2016 Jul; 46(3):142-8. PubMed ID: 26612093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases.
    Sipahi OR; Arda B; Nazli-Zeka A; Pullukcu H; Tasbakan M; Yamazhan T; Ozkoren-Calik S; Sipahi H; Ulusoy S
    Int J Clin Pract; 2014 Feb; 68(2):230-5. PubMed ID: 24372736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients.
    Viscoli C; Cometta A; Kern WV; Bock R; Paesmans M; Crokaert F; Glauser MP; Calandra T;
    Clin Microbiol Infect; 2006 Mar; 12(3):212-6. PubMed ID: 16451406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
    Aynioglu A; Mutlu B; Hacihanefioglu A
    Rev Esp Quimioter; 2016 Apr; 29(2):69-75. PubMed ID: 26888338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia.
    Vural S; Erdem E; Gulec SG; Yildirmak Y; Kebudi R
    Pediatr Int; 2010 Apr; 52(2):262-7. PubMed ID: 19744230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia.
    Ichikawa M; Suzuki D; Ohshima J; Cho Y; Kaneda M; Iguchi A; Ariga T
    Pediatr Blood Cancer; 2011 Dec; 57(7):1159-62. PubMed ID: 21438131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.